BioLargo, Inc. Discusses Record-Breaking Financial Results, Innovation-Pipeline Business Model, and More with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 5, 2023) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a cleantech and life sciences innovator and engineering services solution provider. President and CEO of BioLargo, Inc., Dennis P. Calvert, joined Stock Day host Kevin Davis.

The interview covered the following topics:

• The company's first quarter financial results, including increased revenues from sales of private-label pet odor product Pooph (www.pooph.com),
• Progress at the company's engineering group,
• Progress at subsidiary Clyra Medical and its Bioclynse surgical wound irrigation solution,
• The company's overall innovation development cycle; and
• The company's sodium-sulfur battery technology.

"What we're going to witness, we believe, is exactly what's happening at Pooph has the potential to happen for all the other operating assets in the portfolio," said Mr. Calvert. "In each case, we've done the hardest work to invent, prove up, find first commercial adoption, and then find distribution through partnerships."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8312041-biolargo-inc-discusses-record-breaking-financial-results-innovation-pipeline-business-model-a.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. www.BioLargo.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Announces 288% Revenue Growth in Quarterly Report

Company’s revenues grew 288% compared to the same period last year, and grew 78% compared to the fourth quarter of 2022. The company’s net loss dropped by 68% from the same period last year.

Westminster, CA – May 17, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, yesterday filed its Quarterly Report for the three months ended March 31, 2023 (www.biolargo.com/sec-filings). Company management below provides a summary of the quarterly report’s highlights.

BioLargo will hold an investor webcast on Thursday, May 18, 2023, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/48436

Dennis P. Calvert, the company’s President and CEO, said, “We’re confident that the long-term success of our pet odor control product partnership – Pooph – bolstered by the rollout of key water treatment technologies, will drive our company to our goal of profitability and beyond.”

Company management provides highlights of the quarterly report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business.

Highlights:

• Consolidated revenue for the three months ended March 31, 2023, was $3,742,000, which was a 288% increase over the same period in 2022, and a 78% increase over the previous quarter (Q4 of 2022).
• The company’s net loss was reduced by 68% compared to the same period in 2022, to $494,000.
• Net stockholders’ equity rose to $3,552,000 from $2,011,000 in the fourth quarter of 2022.
• The company ended the quarter with $3,264,000 in cash, compared to $1,851,000 at December 31, 2022.
• A standout performer in BioLargo’s portfolio was ONM Environmental, the company’s odor and VOC control subsidiary, whose revenues grew 491% compared to the same period of 2022, to $3,543,000. ONM Environmental’s operating income also grew 10,569% from the same period of 2022, to $1,387,000. The subsidiary’s significant growth in revenue is largely attributed to the growing success of the pet odor control product Pooph, sold by the company’s partners at Ikigai Marketing Works, LLC, which comprised 90% of its revenues (and 86% of BioLargo company-wide revenues).
• Revenues at BioLargo Engineering, Science & Technologies, LLC decreased by 45% to $193,000, as compared to the same period in 2022, and its operating loss increased to $368,000, as compared to $35,000 in the same period in 2022.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding tanticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q1 2023 Earnings Results Webcast and Conference Call on Thursday, May 18, 2023 - 4:30 PM Eastern Time

Westminster, CA – May 17, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Thursday, May 18, 2023, at 1:30 pm Pacific / 4:30 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three months ended March 31, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link:	https://www.webcaster4.com/Webcast/Page/2448/48436
Teleconference Domestic:	888-506-0062
Teleconference International: Participant Access Code:	973-528-0011 918886

 

To watch or listen to a replay of the teleconference:

 

Teleconference Replay Expiration:	Wednesday, May 31, 2023
Teleconference Replay Domestic:	877-481-4010
Teleconference Replay International:	919-882-2331
Replay Passcode:	48436

 

The webcast replay and accompanying presentation materials will be made available for 90 days on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.    

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Dennis Calvert Interview with Kenny Polcari

BioLargo's President and CEO Dennis P. Calvert sat down for an interview with Kenny Polcari, renowned finance and investor intelligence expert and financial commentator for Fox News, CNBC, and CNN, and more. In this interview, Dennis does a deep dive on what's driving BioLargo's growth, including expanded rollout of Pooph pet odor control products in Walmart stores across the country, the commercial launch of the company's PFAS technology, and its newly acquired sodium-sulfur battery energy storage technology.

Watch the full interview here:

About Kenny Polcari

Polcari is currently the Managing Partner of Kace Capital Advisors, Chief Market Strategist at SlateStone Wealth, sits on the Advisory Board of The Headstrong Project, and is a member of the National Organization of Investment Professionals. He is a Fox Business, CNBC, and CNN financial commentator. He started his career on the floor of the New York Stock Exchange as an institutional broker starting in 1985 and graduated from Boston University, School of Management in 1983 with a Bachelor of Science in Business Administration with a concentration in Finance.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Proactive Investors Interview: BioLargo increasing revenue highlighted by achieving operations net positive cash for first time

 Source: Proactive Investors (https://www.proactiveinvestors.com/companies/news/1011579/biolargo-increasing-revenue-highlighted-by-achieving-operations-net-positive-cash-for-first-time-1011579.html)

BioLargo CEO Dennis Calvert joins Natalie Stoberman from the Proactive studios to share its latest earnings call highlighted by a 132% increase in revenues over 2021, and a 26% decrease in net loss.

Calvert says this growth is highlighted by the company achieving net positive cash from operating activities. Calvert adds that 2022 was BioLargo's strongest year in terms of financial performance, with its Pooph pet odor remover product revenues escalating as it rolls into Walmart stores in the U.S.

BioLargo Annual Report Highlights 132% Annual Revenue Increase, Reduced Net Loss

Westminster, CA – April 3, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its Annual Report, filed March 31, 2023, showed a 132% increase in revenues over 2021, and a 26% decrease in net loss (www.biolargo.com/sec-filings). Company management below provides a summary of the annual report’s highlights, including the company’s financial performance and progress of key projects.

BioLargo will hold an investor webcast today, Monday, April 3, 2023, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/47877

Dennis P. Calvert, the company’s President and CEO, said, “2022 was our strongest year yet in terms of financial performance, and we are eager for the day when our valuation reflects the significance of our ongoing success. With Pooph revenues leading the way and other key catalysts like our PFAS treatment business just now coming online, we’re confident that this year will herald even more significant growth at the company.”

Company management provides highlights of the annual report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business, including the risk factors beginning at page 12.

Key financial highlights:

• Consolidated revenue for the year ended December 31, 2022, was $5,884,000, which was a 132% increase over 2021. Revenue in the fourth quarter of 2022 was $2,096,000, a 40% increase as compared with the third quarter of 2022 (quarter-over-quarter), and a 167% increase as compared with the fourth quarter of 2021.
• The company no longer has any outstanding convertible debt.
• The company’s total net loss for the year ended December 31, 2022, was reduced by 26% as compared with the prior year, from $6,894,000 to $5,132,000. Approximately 50% of the company’s net loss was due to non-cash expenses, including $2,071,000 of stock option compensation expense, and $291,000 of services paid by the issuance of our common stock. Net cash used in operations decreased 30% to negative $2,760,000.
• Net stockholders’ equity rose from $933,000 at the end of 2021 to $2,011,000 at the end of 2022.
• The company ended the year with $3.1 million in current assets and working capital of $1.6 million.

Key commercial and developmental highlights:

• Revenues from sales of the Pooph pet odor control product to Ikigai Marketing Works have escalated significantly, resulting from the ongoing success of Ikigai’s national marketing campaign for the product and its rollout into Walmart stores in the US.
• The company’s AEC water treatment system has been tested and proven to remove per- and polyfluoroalkyl substances (PFAS) from water to below levels required by the EPA’s recently proposed limitations of four parts per trillion. These so-called “forever chemicals” accumulate in the human body, are linked to multiple health issues, and are more and more the subject of government regulatory concern.  
• The company acquired the IP rights to a sodium-sulfur battery, a technology with unique technical features that enable it to address a need in the market for safe, affordable, long-term energy storage at grid-scale, at electric vehicle charging stations, or similar static applications. The technology is already developed, and BioLargo has formed and secured seed capital for a new subsidiary which will lead the manufacturing, scale-up, and operations for the new technology.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo, Inc. Discusses 125% Revenue Increase and Significance of Proposed EPA PFAS Regulations with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - March 29, 2023) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO) (the "Company"), a cleantech and life sciences innovator and engineering services solution provider. CEO of the Company, Dennis P. Calvert, joined Stock Day host Everett Jolly.

"We saw your announcement about your 2022 revenues being 125% higher than the previous year. What accounted for such a dramatic increase?", asked Jolly. "We partnered with a group called Ikigai Marketing Works and created a product called Pooph," Calvert explained. "Walmart recently announced that they will be going nationwide with it in Q2," said Calvert, adding that the product is being advertised on television nationally. "Chewy, one of the largest online retailers, has picked it up, along with other retailers."

Calvert elaborated, "We sell our product to them on a wholesale basis and we get a royalty on sales. We also bargained to participate in their equity," he added, noting that the equity agreement is for 20% of the company. "It is a great business model for BioLargo," said Calvert. "This is our number one mover right now, and I think we are just scratching the surface."

"Can you give us an update on your treatment technology for PFAS, also known as 'forever chemicals', in water?", asked Jolly. "Well, the EPA finally came out with the proposed detection limits of four parts per trillion," said Calvert. "With the limits being so low, it expands the scope of the market astronomically, and will include not just drinking water but water used in food production, cosmetics, and other industrial applications," he explained, adding that PFAS chemicals have been linked to birth defects and cancer.

Calvert discussed the Company's own PFAS treatment device, which recently secured its first customer. "To get mass adoption, we need to show full-scale adoption," said Calvert. "We have done about ten trials," he added. "We now have national representation on channel partners, ten agreements have been signed, and we are now getting three to four projects per week proposed to us," shared Calvert. "The pending list of opportunities is worth well over 100 million."

"To our knowledge, we are the only commercially viable technology that makes the claim that it can achieve a non-detect status," continued Calvert. "It is a significant claim, and we have proven it."

Jolly then asked about the Company's recently announced acquisition of a sodium-sulfur battery technology. "One of the co-developers and engineers, who spent five to eight years refining the design to make a sodium-sulfur battery, brought this technology to us," said Calvert. "We acquired the technology and brought the engineer and co-developer to our team, now we are in the replication process for the battery," he explained, adding that the battery is designed to fill a void in the market for safe, long-term fixed site energy storage, like EV charging stations, renewable energy production sites, and grid-scale energy storage.

"Lithium has its drawbacks; it cannot be charged to 100% and cannot be discharged to 0%, it also has a limited functional life," continued Calvert. "We believe we could get a 20-year battery from this with no rare Earth elements, as well as incredible efficiency and a low cost of materials," he explained, adding that the battery also has a much lower risk of runaway fire compared to lithium-ion based technologies which can be highly explosive.

To close the interview Calvert encouraged listeners and shareholders to keep up to date on the Company's current and upcoming projects as they continue to expand and grow an innovative pipeline of technologies.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8271999-biolargo-inc-discusses-125-revenue-increase-and-significance-of-proposed-epa-pfas-regulations.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. www.BioLargo.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.